Autor: |
Liangyun Li, Shaoxi Diao, Zixiang Chen, Jintong Zhang, Wei Chen, Tianqi Wang, Xin Chen, Yuxin Zhao, Tao Xu, Cheng Huang, Jun Li |
Jazyk: |
angličtina |
Rok vydání: |
2023 |
Předmět: |
|
Zdroj: |
Pharmacological Research, Vol 193, Iss , Pp 106808- (2023) |
Druh dokumentu: |
article |
ISSN: |
1096-1186 |
DOI: |
10.1016/j.phrs.2023.106808 |
Popis: |
Hepatic fibrosis is caused by liver damage as a consequence of wound healing response. Recent studies have shown that hepatic fibrosis could be effectively reversed, partly through regression of activated hepatic stellate cells (HSCs). Transcription factor 21 (TCF21), a member of the basic helix-loop-helix (bHLH) transcription factor, is involved in epithelial-mesenchymal transformation in various diseases. However, the mechanism by which TCF21 regulates epithelial-mesenchymal transformation in hepatic fibrosis has not been elucidated. In this research, we found that hnRNPA1, the downstream binding protein of TCF21, accelerates hepatic fibrosis reversal by inhibiting the NF-κB signaling pathway. Furthermore, the combination of DNMT3a with TCF21 promoter results in TCF21 hypermethylation. Our results suggest that DNMT3a regulation of TCF21 is a significant event in reversing hepatic fibrosis. In conclusion, this research identifies a novel signaling axis, DNMT3a-TCF21-hnRNPA1, that regulates HSCs activation and hepatic fibrosis reversal, providing a novel treatment strategy for hepatic fibrosis. The clinical trial was registered in the Research Registry (researchregistry9079). |
Databáze: |
Directory of Open Access Journals |
Externí odkaz: |
|